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A higher incidence of thrombotic events, mainly pulmonary embolism (PE), has been
reported in hospitalized patients with COVID-19. The main objective was to assess clinical
and laboratory differences in hospitalized COVID-19 patients according to occurrence of PE.
Methods
This retrospective study included all consecutive patients hospitalized with COVID-19 who
underwent a computed tomography (CT) angiography for PE clinical suspicion. Clinical data
and median blood test results distributed into weekly periods from COVID-19 symptoms
onset, were compared between PE and non-PE patients.
Results
Ninety-two patients were included, 29 (32%) had PE. PE patients were younger (63.9 (SD
13.7) vs 69.9 (SD 12.5) years). Clinical symptoms and COVID-19 CT features were similar
in both groups. PE was diagnosed after a mean of 20.0 (SD 8.6) days from the onset of
COVID-19 symptoms. Corticosteroid boluses were more frequently used in PE patients
(62% vs. 43%). No patients met ISTH DIC criteria. Any parameter was statistically signifi-
cant or clinically relevant except for D-Dimer when comparing both groups. Median values
[IQR] of D-dimer in PE vs non-PE patients were: week 2 (2010.7 [770.1–11208.9] vs 626.0
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[374.0–2382.2]; p = 0.004); week 3 (3893.1 [1388.2–6694.0] vs 1184.4 [461.8–2447.8]; p =
0.003); and week 4 (2736.3 [1202.1–8514.1] vs 1129.1 [542.5–2834.6]; p = 0.01). Median
fold-increase of D-dimer between week 1 and 2 differed between groups (6.64 [3.02–23.05]
vs 1.57 [0.64–2.71], p = 0.003); ROC curve AUC was 0.879 (p = 0.003) with a sensitivity and
specificity for PE of 86% and 80%, respectively.
Conclusions
Among hospitalized COVID-19 patients, D-dimer levels are higher at weeks 2, 3 and 4 after
COVID-19 symptom onset in patients who develop PE. This difference is more pronounced
when the fold increase between weeks 1 and 2 is compared.
Introduction
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome corona-
virus-2 (SARS-CoV-2). First reported in Hubei (China) at the end of 2019, COVID-19 rapidly
spread worldwide and was declared a pandemic on March 11th, 2020 [1,2]. An unexpectedly
high incidence of thrombotic events, mainly pulmonary embolism (PE), has been reported
among patients hospitalized with COVID-19, particularly in intensive care units (ICU) [3–5].
Moreover, PE is a major worldwide health issue and the leading preventable cause of death in
hospitalized patients [6].
Some studies have suggested that COVID-19 triggers a hypercoagulable state induced by
hypoxia, immobilization, inflammation and cytokine storm syndrome, along with damage
to endothelial cells [7,8]. More than one third of hospitalized patients with COVID-19
shows elevated D-dimer levels and D-dimer values are even higher in patients with severe
COVID-19 than in those with mild disease [9–12]. Furthermore, endothelial dysfunction
may cause blood coagulation and activation of platelet aggregation leading to vascular
microthrombosis, which is considered a linchpin in the pathogenesis of the hypercoagulable
state in COVID-19 [13–15]. It cannot yet be ruled out that pulmonary endovascular filling
defects found in these patients are caused by a local thrombotic phenomenon rather than
true thromboembolism [13,16].
The use of prophylactic doses of low-molecular-weight heparins (LMWH) is now widely
recommended for patients hospitalized with COVID-19 [17,18]. However, a high incidence of
thrombotic events, mainly PE, has been reported despite the administration of standard
thromboprophylactic doses [3,5,19]. In fact, some authors state that prophylactic-doses of
LMWH might not be sufficient to deal with the COVID-19-related hypercoagulable state and
that higher LMWH doses should be considered in hospitalized COVID-19 patients without
documented venous thromboembolism [18,20,21].
There are two overlapping pathological subsets in COVID-19: the first is triggered by the
virus itself and the second relates to the host response. Because of this dynamic clinical
course, a staged clinical classification has been proposed [22]. This strategy is widely
accepted, and clinicians generally assess COVID-19 in terms of weeks since onset of symp-
toms. However, the evidence on risk factors for PE in COVID-19 patients from this
dynamic perspective is scarce and most studies are focused on ICU patients [3,5,23,24]. The
aim of our study was to compare clinical characteristics and laboratory data at different dis-
ease stages amongst patients hospitalized for COVID-19, according to the presence of PE
detected on computed tomography (CT) scan.
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Material & methods
Study design and patients
This was a retrospective, non-interventional study that included all consecutive patients admit-
ted to the Hospital Universitari de Bellvitge (Barcelona, Spain) from March 1st to April 24th,
2020 who met the inclusion criteria. During this period, a total of 2,558 patients attended the
Emergency Department due to COVID-19 symptoms and 1,287 were admitted. The inclusion
criteria were: 1) patients�18 years of age, 2) admission for COVID-19 pneumonia, and 3)
chest CT angiography for clinical suspicion of PE during the study period. Clinical suspicion
of PE was defined as new or worsening dyspnea or oxygen desaturation and/or chest pain, syn-
cope or hemodynamic instability with no other alternative diagnosis. Given the 50%-80% sen-
sitivity for SARS-CoV-2 real-time PCR, patients were also adjudicated as having COVID-19 if
CT scan results were considered typical of the disease (i.e., extensive bilateral and peripheral
ground glass opacities and/or alveolar consolidation), and if symptoms and/or blood test
results were consistent with COVID-19 in the absence of an alternative diagnosis [25,26].
Patients with no contrast-enhanced chest CT scan were excluded, as were patients who were
diagnosed with COVID-19 during a hospital stay for other medical conditions.
Data were obtained from routine daily practice and anonymized. Personal and clinical data
collected for the study are in line with the Spanish Data Protection Act (Ley Orgánica 3/2018
de 5 de diciembre de Protección de Datos Personales). Informed consent was waived due to
mandatory isolation measures in hospital care for these patients and because this was a retro-
spective study. The protocol was approved by the Ethics Committee of the Hospital Universi-
tari de Bellvitge (Barcelona, Spain; approval number PR178/20). We followed the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement
guidelines for observational cohort studies [27].
Variables
The following parameters were collected: patient baseline clinical characteristics; comorbid-
ities (such as chronic heart, lung or kidney disease); concomitant therapies; risk factors for
venous thromboembolism (VTE); treatment received upon PE diagnosis; drug and dose of
anticoagulant therapy; and outcomes during hospitalization. Disseminated intravascular
coagulation (DIC) and sepsis-induced coagulopathy (SIC) were defined according to ISTH
criteria [28].
Immobilized patients were those who had been immobilized for surgical or non-surgical
reasons occurred within two-months prior to hospital admission. Active cancer was defined as
a diagnosed malignancy, irrespective of administration of anti-cancer treatment. Chronic lung
disease was defined as chronic obstructive pulmonary disease, asthma, interstitial lung disease
or obstructive sleep apnea syndrome.
For normotensive patients with PE, stratification using the simplified version of the Pulmo-
nary Embolism Severity Index (sPESI) was assessed [29]. All bleeding events were classified as
‘major’ according to ISTH criteria [30].
CT protocol and imaging analysis
The routine protocol implemented in our department for patients with suspected PE is multi-
detector pulmonary CT angiography with 16-slice multi-detector CT (Toshiba Aquilion RXL)
after intravenous injection of 60 ml iodinated contrast agent (Rovi Iomeron) at a flow rate of 4
ml/s, triggered on the main pulmonary artery. CT scan settings were 100 kVp, rotation time 5
s, average tube current 500 mA and pitch 1×16. All chest CT scans with patterns consistent
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with COVID-19 and presence of PE were reviewed by 2 expert thoracic radiologists blinded to
patient status and clinical and laboratory test results.
Blood tests
All consecutive blood tests were collected between admission and discharge. Routine
hematological parameters were measured using Sysmex XN series instruments provided
by Roche Diagnostics. These included hemoglobin levels and platelet, white blood cell,
lymphocyte and neutrophils counts. Blood biochemistry parameters [urea, creatinine, glo-
merular filtration rate, aspartate aminotransferase, alanine aminotransferase, lactate dehy-
drogenase (LDH), creatine kinase (CK), troponin, albumin, procalcitonin, triglycerides,
C-reactive protein, ferritin and interleukin-6] were measured using a Cobas c6000 analyzer
and a Cobas c8000 analyzer (Roche Diagnostics, Mannheim, Germany). Coagulation
parameters (prothrombin time, activated partial thromboplastin time and fibrinogen) and
D-dimer levels were determined using an ACL TOP 750 System and ACL TOP 500 (Instru-
mentation Laboratory, Germany). For D-dimer, the upper normal limit was set at 250 μg/
L, except for those patients aged over 50 years for whom we used the recommended age-
adjusted cut-off (age × 10) [31].
All results were stored in the OMNIUM database, from SUNSET Technologies (Girona,
Spain), and were recovered by the Cobas Infinity (Roche) software that integrates all labo-
ratory information systems from our hospital. Since the primary objective of the study
focused on the development of PE, blood tests were collected before PE diagnosis by CT,
while those collected after diagnosis were disregarded. The widely accepted three-stage
classification for COVID-19 was used, so blood test results were distributed into six periods
of one week [22].
Statistical analysis
All categorical variables are expressed as frequencies and proportions, and continuous
variables as means with standard deviation (SD) or median with interquartile range
[IQR]. Normality of the distribution was assessed using the one-sample Kolmogorov-
Smirnov test. For those variables that were not normally distributed, results are presented
as medians with IQR. If more than one blood test of a given patient was available in the
same weekly period, mean (SD) values were used. All variables were compared between
patients with and without PE at thoracic CT angiography. We used Chi-square or Fisher’s
exact tests to compare categorical data between groups. Two-tailed unpaired Student t-
tests were used to compare normally distributed continuous data, and the Mann-Whitney
U test for non-normally distributed continuous data comparisons. For those statistically
different parameters, fold change from the upper normal limit at different weekly time-
points were also calculated comparing PE and non-PE patients. Furthermore, to assess
dynamic differences between consecutive one-week periods, we also calculated fold
increases by dividing the parameter values from a week by the parameter values from the
previous week. Because of the observational and descriptive nature of our study, designed
without regard to causal hypotheses, adjustment for multiple comparison was not per-
formed [32]. The area under the curve (AUC) and the 95% confidence interval (CI) of the
receiver operating characteristic (ROC) curve were obtained. The optimal cut-off points
to predict PE were determined by Youden’s J statistic [33]. A two-sided p-value less than
0.05 was statistically significant. Analyses were performed using IBM SPSS Statistics, ver-
sion 19.0 for the PC.
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Results
Baseline characteristics
Overall, 2,447 CT scans were performed during the study period and 101 patients who under-
went contrast-enhanced chest CT for PE suspicion, were selected. Five patients were referred
to another center and four were not hospitalized, so 92 patients were finally included in the
study (Fig 1). A positive RT-PCR result for SARS-CoV-2 was obtained from 91 patients; diag-
nosis was based on CT images, clinical symptoms, and blood test data consistent with
COVID-19 in one case. Mean age was 68.1 (SD 13.2) years, most patients were male (74%) and
Caucasian (90%). PE was objectively confirmed in 29 (32%) patients. Patients who developed
PE were significantly younger (63.9 [SD 13.7] vs 69.9 [SD 12.5] years) and less frequently
Fig 1. Patient selection.
https://doi.org/10.1371/journal.pone.0243533.g001
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presented arterial hypertension (41% vs 64%). Clinical characteristics of patients according to
PE diagnosis are shown in Table 1.
In-hospital clinical characteristics according to PE
There were no statistically significant differences related to symptom type or time since onset
before admission among PE and non-PE patients. On admission, both groups showed similar
hemodynamics, oxygenation parameters and ventilation requirements. COVID-19-related CT
findings were similar in both groups. All patients received similar experimental drugs for treat-
ing the disease, except for corticosteroid bolus, which was used more frequently in PE patients
(62% vs 43%). None of the patients achieved ISTH criteria for DIC and less than 4% did so for
SIC criteria (3% vs 3%). All patients received thromboprophylaxis from admission, except
those who were already receiving anticoagulation therapy (3% PE vs 6% non-PE patients) and
Table 1. Clinical characteristics of patients according to the diagnosis of PE.
With PE N = 29 Without PE N = 63 p-value
Age, years; mean (SD) 63.9 (SD 13.7) 69.9 (SD 12.5) 0.039
Gender male, n (%) 23 (79%) 45 (71%) 0.424
Race Caucasian, n (%) 26 (90%) 57 (91%) 0.889
Body mass index; mean (SD) 30.2 (SD 5.3) 28.7 (SD 4.2) 0.199
Smoking behavior, n (%) 0.525
Never smoker 17 (59%) 42 (67%)
Current smoker 1 (3%) 4 (6%)
Former smoker 11 (38%) 17 (27%)
Alcohol history, n (%) 2 (7%) 4 (6%) 0.460
Comorbidity, n (%)
Arterial hypertension 12 (41%) 40 (64%) 0.047
Diabetes mellitus 5 (17%) 22 (35%) 0.084
Dyslipidemia 11 (38%) 28 (44%) 0.516
Chronic lung disease 6 (21%) 14 (22%) 0.868
Chronic kidney disease 2 (7%) 11 (18%) 0.215
Atrial fibrillation 0 2 (3%) 0.490
Ischemic heart disease 1 (3%) 5 (8%) 0.661
Cerebrovascular disease 2 (7%) 3 (5%) 0.649
Peripheral arteriopathy 0 3 (5%) 0.549
Pharmacological therapies at presentation, n (%)
Antihypertensive medication 12 (41%) 37 (59%) 0.121
Antidiabetic medication 4 (14%) 19 (30%) 0.085
Statins 8 (28%) 24 (38%) 0.325
Antiplatelet therapy 3 (10%) 15 (24%) 0.114
Anticoagulant therapy 1 (3%) 4 (6%) 1.000
Hydroxychloroquine 0 0 -
Risk Factors for Venous Thromboembolism (VTE), n (%)
Previous thrombosis 3 (10%) 6 (9%) 1.000
Family history of VTE 1 (3%) 0 0.315
Antiphospholipid syndrome 1 (3%) 0 0.315
Immobility 1 (3%) 5 (8%) 0.661
Cancer 1 (3%) 5 (8%) 0.661
Use of contraceptives 0 0 -
https://doi.org/10.1371/journal.pone.0243533.t001
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nine patients diagnosed with PE in the Emergency Department who immediately initiated
anticoagulant treatment. Pharmacological thromboprophylaxis consisted of 3500 IU bemi-
parin OD or enoxaparin 40 mg OD or higher enoxaparin doses (including 40 mg BID or from
0.5 to 0.75 mg/kg BID). Interestingly, amongst the 15 patients who received higher enoxaparin
doses for thromboprophylaxis, six patients developed PE while nine did not.
PE was suspected, and so on a thoracic CT performed, because of new or worsening dys-
pnea or oxygen desaturation in 78 (84.8%) patients, syncope or hemodynamic instability in 10
(10.9%) patients or chest pain in four (4.3%) patients. PE was diagnosed after 20 (SD 8) days
from the onset of COVID-19 symptoms. At time of PE diagnose, eight patients (28%) were
admitted in the ICU while the other 21 (72.4%) were admitted in a medical ward. No signifi-
cant differences were observed in terms of ICU admission at time of PE clinical suspicion
when comparing PE and no PE groups (p = 0.084) Most PE were bilateral (52%) and the most
proximal vessel involved was subsegmental in 10%, segmental in 34%, lobar in 31% and main
pulmonary artery in 24%. PE features are shown in S1 Table. All patients received anticoagu-
lant treatment with LMWH after PE diagnosis and no thrombolytic therapy or inferior vena
cava filters were used. Major bleeding were significantly more frequent in PE patients (24% vs
8%); one non-PE patient with major bleeding was receiving higher doses of enoxaparin for
thromboprophylaxis. Mortality was similar in both groups (27% vs 20%). COVID-19-related
characteristics and in-hospital outcomes of patients according to PE are shown in Table 2.
Analysis of clinical laboratory data determinations associated with PE
Data from all blood tests were grouped by weeks from COVID-19 symptoms onset and com-
pared between PE and non-PE patients. Some differences were detected, but very few reached
statistical significance (S2 Table). After discarding some clinically irrelevant variations, statisti-
cally significant differences were only observed in median values [IQR] of D-dimer between PE
and non-PE patients at week 2 (2010.7 [770.1–11208.9] vs 626.0 [374.0–2382.2]; p = 0.004);
week 3 (3893.1 [1388.2–6694.0] vs 1184.4 [461.8–2447.8]; p = 0.003); and week 4 (2736.3
[1202.1–8514.1] vs 1129.1 [542.5–2834.6]; p = 0.01) (Fig 2A). ROC analyses for D-dimer in
these different weekly periods provided AUC values of 0.727 (p = 0.004), 0.743 (p = 0.003) and
0.746 (p = 0.01), respectively (Fig 2B). The optimal D-dimer cut-off points for PE according to
Youden’s J statistic at weeks 2, 3 and 4 were 632 ug/L (J: 0.42), 2036 ug/L (J: 0.44) and 2271 ug/L
(J: 0.42), respectively. D-dimer comparisons using different reference ranges (reference normal
range, age-adjusted and Youden’s J statistic cut-offs) according to PE, are shown in S3 Table.
We also studied the magnitude of the difference in D-dimer levels compared to normal val-
ues. To this end, we calculated the D-dimer fold change from the age-adjusted upper normal
limit at different weekly timepoints comparing PE and non-PE patients. Median [IQR] fold
changes were significantly higher in patients with PE than in those without PE, also at week 2
(2.83 [1.37–26.16] vs 0.92 [0.57–3.34], p = 0.004), week 3 (6.93 [2.17–13.04] vs 1.81 [0.69–3.5],
p = 0.006) and week 4 (4.45 [1.88–12.16] vs 1.66 [0.79–5.73], p = 0.013). ROC analyses of these
D-dimer fold changes at weeks 2, 3 and 4 yielded AUC values of 0.737 (p = 0.004), 0.735
(p = 0.006) and 0.745 (p = 0.013), respectively. The optimal D-dimer fold increase cut-off point
for PE at weeks 2, 3 and 4 resulted in 1.41 (J: 0.39), 3.77 (J: 0.45) and 1.83 (J: 0.37), respectively.
All sensitivity and specificity results for these cut-off points are shown in Table 3.
Analysis of clinical laboratory data fold increases between weeks associated
with PE
As stated in methodology section, we calculated weekly fold increases for all blood test param-
eters and compared them between PE and non-PE patients. The only statistically significant
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and clinically relevant difference among PE and non-PE patients was D-dimer fold increase
between the first and second week after COVID-19 symptom onset (6.64 [3.02–23.05] vs 1.57
Table 2. COVID19-related characteristics of patients during hospital stay, according to the diagnosis of PE.
PE N = 29 Non-PE N = 63 p-value
Days of symptoms before admission, mean (SD) 9.6 (SD 5.2) 7.5 (SD 5.8) 0.104
Symptoms, n (%)
Fever 25 (86%) 51 (81%) 0.537
Cough 21 (72%) 48 (76%) 0.698
Dyspnea 18 (62%) 42 (67%) 0.667
Arthromyalgia 13 (45%) 30 (48%) 0.803
Diarrhea 11 (38%) 22 (35%) 0.780
Anosmia 1 (3%) 6 (10%) 0.426
Dysgeusia 2 (7%) 7 (11%) 0.714
Admission
SBP 136.7 (SD 21.4) 128.3 (SD 18.7) 0.061
Sat O2 93 (SD 5.7) 94.1 (SD 4.9) 0.337
Sat O2/Fi O2, mean (SD) 367.4 (SD 127.7) 392.6 (SD 102.7) 0.318
Length of stay (days), median (IQR) 20 (9.5–31.5) 17 (11–30) 0.791
COVID-related treatment, n (%)
Hydroxychloroquine 28 (97%) 62 (98%) 0.533
Lopinavir/Ritonavir 22 (76%) 44 (70%) 0.389
Remdesivir 1 (3%) 3 (5%) 1.000
Tocilizumab 13 (45%) 24 (38%) 0.541
Corticosteroid bolus 18 (62%) 27 (43%) 0.044
Low-tapering corticosteroid therapy 9 (31%) 16 (25%) 0.441
DIC score� 5 0 0 -
SIC score� 4 1 (3.4) 2 (3.2) 1.000
Thromboprophylaxis 28 (96%) 59 (93%) 1.000
Higher doses enoxaparin 6 (21%) 9 (14%) 0.484
Days of onset symptoms to CT 20 (SD 8) 19 (SD 9) 0.703
SatO2/FiO2 at CT, mean (SD) 249 (SD 140) 286 (SD 134) 0.265
Pulmonary involvement in CT scan
Bilateral pattern 25 (86%) 60 (95%) 0.201
Organizing pneumonia pattern 11 (38%) 20 (32%) 0.560
Ground glass pattern 24 (83%) 56 (89%) 0.508
Acute alveolar damage 4 (14%) 2 (3%) 0.076
Pneumo -thorax/-mediastinum 2 (7%) 1 (2%) 0.233
Lower limbs deep venous thrombosis/Doppler US 6 (21%)/6 6 (10%)/12 0.054
Non-invasive/Invasive ventilation 11 (37%) 11 (18%) 0.087
Admission in ICU when PE clinical suspicion 8 (28%) 7 (11%) 0.084
Admission in ICU/step down unit during hospitalization 12 (41%) 14 (22%) 0.289
Bleeding 7 (24%) 5 (8%) 0.046
Major 5 (17%) 4 (6%) 1.000
RBC transfusion 4 (14%) 4 (6%) 0.576
Embolization 1 (3%) 2 (3%) 0.523
Mortality 8 (28%) 13 (20%) 0.485
SBP, Systolic Blood Pressure; DIC, disseminated intravascular coagulation; SIC, sepsis-induced coagulopathy; CT, computed tomography; US, ultrasound; ICU,
Intensive Care Unit; RBC, red blood cells.
https://doi.org/10.1371/journal.pone.0243533.t002
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Fig 2. D-Dimer throughout time and its relationship with pulmonary embolism. Panel A: D-Dimer blood level
means through weeks from COVID19 symptoms onset, comparing patients with (green) and without PE (blue). Red
circles represent each pulmonary embolism event in the week they were diagnosed. Panel B: Comparison of the
different D-Dimer level ROC curves at week 2 (green), week 3 (blue) and week 4 (red). Panel C: ROC curve of
D-Dimer fold change between first and second week.
https://doi.org/10.1371/journal.pone.0243533.g002
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[0.64–2.71], p = 0.003). The AUC of the ROC curve was 0.879 (p = 0.003) (Fig 2C) and the
optimal cut-off point according to Youden’s J statistic of D-dimer ratio between first and sec-
ond week was 2.87 (J: 0.66). The prediction efficiency of all ROC analyses and sensitivity and
specificity values are shown in Table 3.
Discussion
Though similar previous studies, this is the first one to report all blood tests performed in hospi-
talized COVID-19 patients by one-week periods, comparing groups with and without PE
[23,24,34,35]. In a non-COVID-19 scenario, the negative predictive value of D-dimer testing is
high, but the positive predictive value of elevated D-dimer levels is low. Therefore, in that setting,
D-dimer testing is not useful for confirmation of PE, making pretest probability a key step in the
diagnostic algorithm for PE [36]. However, symptoms of PE overlap with symptoms of COVID-
19 pneumonia, so clinical suspicion of PE may be particularly challenging in patients hospitalized
with COVID-19 illness. This is of clinical relevance, because COVID-19 patients often have
severe hypoxemia, pulmonary hypertension due to hypoxic pulmonary vasoconstriction, or right
ventricular failure, and an undiagnosed PE may be unrecoverable in such patients [4,5,19].
Although PE Wells score has been retrospectively used in a previous study, current clinical deci-
sion rules for PE diagnosis have not been validated for hospitalized patients in the COVID-19 sce-
nario [34]. Worryingly, most hospitalized COVID-19 patients show elevated D-dimer levels,
mainly in the ICU setting [8,23,34]. Therefore, the validation of previous predictive scores or the
design of new specific ones, using new D-dimer cut-offs that reflect the course of the disease over
time, are needed for assessing the clinical probability of PE in COVID-19 scenario.
Table 3. AUC-ROC of D-dimer with various methods at different weeks from COVID19 symptoms onset.
PE No PE AUC (CI) p-value Optimal Cut-off (Youden’s J) Sensitivity Specificity
Median (IQR) Median (IQR)
Blood levels (μg/L)
Week 1 390 (200–1795) 742 (340–2603) 0.364 (0.140–0.587) 0.223 - - -
Week 2 2011 (770–11209) 626 (374–2382) 0.727 (0.605–0.849) 0.004 632 pg/mL (J: 0.42) 89% 53%
Week 3 3893 (1388–6694) 1184 (462–2448) 0.743 (0.619–0.867) 0.003 2036 pg/mL (J: 0.44) 75% 69%
Week 4 2736 (1202–8514) 1129 (543–2835) 0.746 (0.605–0.886) 0.010 2271 pg/mL (J: 0.42) 67% 75%
Week 5 1916 (808–2672) 981 (719–2071) 0.600 (0.343–0.857) 0.425 - - -
Week 6 626 (341–2489) 586 (368–1273) 0.529 (0.206–0852) 0.845 - - -
Fold change from normal upper limit
Week 1 1.56 (0.4–5.49) 1.14 (0.72–4.43) 0.48 (0.245–0.714) 0.855 - - -
Week 2 2.83 (1.37–26.16) 0.92 (0.57–3.34) 0.737 (0.608–0.866) 0.004 1.41 (J: 0.39) 77% 63%
Week 3 6.93 (2.17–13.04) 1.81 (0.69–3.5) 0.735 (0.606–0.863) 0.006 3.77 (J: 0.45) 67% 78%
Week 4 4.45 (1.88–12.16) 1.66 (0.79–5.73) 0.745 (0.594–0.897) 0.013 1.83 (J: 0.37) 82% 55%
Week 5 3.36 (1.4–4.51) 1.58 (1.13–4.12) 0.611 (0.371–0.852) 0.374 - - -
Week 6 1.93 (0.67–3.74) 1.2 (0.6–1.8) 0.612 (0.277–0.947) 0.457 - - -
Fold change from previous week
Week 2/Week 1 6.64 (3.02–23.05) 1.57 (0.64–2.71) 0.879 (0.748–1) 0.003 2.87 (J: 0.66) 86% 80%
Week 3/Week 2 3.25 (2.61–8.61) 1.24 (0.71–4.06) 0.668 (0.469–0.867) 0.086 - - -
Week 4/Week 3 0.48 (0.26–3.14) 0.91 (0.43–1.66) 0.392 (0.147–0.637) 0.317 - - -
Week 5/Week 4 0.80 (0.21–1.07) 0.68 (0.49–1.73) 0.453 (0.216–0.691) 0.713 - - -
Week 6/Week 5 1.04 (0.24–1.67) 0.71 (0.4–0.9) 0.588 (0.200–0.977) 0.557 - - -
Abbreviations: IQR: Interquartile range; AUC: Area under the curve; ROC: Receiver operating characteristic curves; CI: Confidence interval.
https://doi.org/10.1371/journal.pone.0243533.t003
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We have determined the use of D-dimer levels in the COVID-19 scenario to calculate the
clinical probability of PE, although this approach is the opposite to the already conventional
use of D-dimer to rule out this event [36]. Grouping these results into one-week periods helps
clinicians to identify the proposed disease stages and provides guidance to their findings [22].
We have found that after the viral response phase of the first week, D-dimer is the most useful
factor for classifying hospitalized COVID-19 patients according to their risk of PE. Indeed, we
have objectively confirmed the presence of higher D-dimer levels in weeks 2, 3 and 4 in
patients with a diagnosis of PE during hospitalization. According to our findings, a 2.87-fold
increase in D-dimer levels in the second week from COVID-19 symptoms onset, compared to
the first week, has a sensitivity and specificity for predicting PE of 86% and 80%, respectively.
Regarding clinical management in our series, the use of corticosteroid boluses was more
common in patients presenting PE. Although a relationship between corticosteroid therapy
and VTE has been previously described, early interventions aimed at reducing inflammation,
such as dexamethasone, might help to prevent this hypercoagulable state [37]. In fact, treat-
ment to counteract inflammation and cytokine storm syndrome has been related with lower
mortality and with an improvement of inflammatory-induced hypercoagulability in COVID-
19 patients [37–39]. This is important because we have observed that PE was diagnosed mostly
between 2–4 weeks after onset of symptoms, which means that PE occurs during or immedi-
ately after the systemic hyperinflammation stage, consistent with the thromboinflammation
term [39–41]. Indeed, inflammatory parameters, such as C-reactive protein or ferritin, were
higher during these weeks in PE patients than in non-PE patients, though non-statistically sig-
nificant. The inflammatory storm in COVID-19 can damage the microvasculature and cause
endothelial dysfunction, which could trigger a hypercoagulable state [41,42]. In fact, when
endothelial dysfunction occurs, it leads to dysregulation of coagulation and complement and
platelet activation, mainly mediated by α-thrombin [11,40,43]. According to our results,
higher D-dimer values detected in PE patients compared to non-PE patients could reflect
more intense endothelial damage and, consequently, a severe hypercoagulable state. Addi-
tional insight into possible individual factors related to PE developing during COVID-19 hos-
pitalization is warranted.
SIC can be considered an earlier phase of DIC [28]. Although 3% of our PE patients met
ISTH SIC criteria, none met DIC criteria. This suggests that severe COVID-19 is associated
with coagulation derangements resulting in a hypercoagulable state rather than a consumption
coagulopathy [8]. Although specific drivers of this coagulopathy in COVID-19 are uncertain,
it is known that SARS-CoV-2 can bind ACE2 and injure endothelial cells, leading to tissue fac-
tor expression and activation of the coagulation cascade. Elevated D-dimers may be a bio-
marker of this pathway [9,44]. Indeed, we have found that those patients who developed PE
during hospitalization showed higher D-dimer levels. These differences were statistically sig-
nificant at weeks 2, 3 and 4, and also when compared with upper normal limit age-adjusted
cut-off (age × 10) [31].
Once a thrombotic event such as PE occurs, anticoagulant treatment is recommended [18].
Controversy surrounds the doses of anticoagulants to be used in COVID-19 patients without a
diagnosis of VTE. Although most authors recommend prophylactic anticoagulation, others
suggest intermediate-dose parenteral medication or therapeutic anticoagulation [18]. Two ret-
rospective studies suggested that anticoagulation treatment was associated with a reduced risk
of mortality, but the efficacy and safety of higher doses of LMWH are still debated and may
lead to undesirable events, such as those hemorrhagic complications observed in our study.
The use of intermediate or full therapeutic dose of anticoagulation agents needs to be
addressed in randomized clinical trials, of which some are ongoing. Moreover, because PE is
usually diagnosed some days after admission, early thromboprophylaxis during hospitalization
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for COVID-19 patients is recommended and should be the first step to prevent VTE [18,20].
However, since most of our PE patients were diagnosed between the week 2 and 4 after
COVID-19 symptoms onset, it is important to have tools in clinical practice to identify
patients at risk of developing PE despite thromboprophylaxis, mostly in ICU patients [35].
The present study has some limitations that should be mentioned. Firstly, the retrospective
nature of the study, in which only patients with contrast-enhanced chest CT were considered,
making the real PE incidence difficult to assess. Secondly, the relatively small size of the sam-
ple. However, we point out that this is the first study assessing all the commonly used blood
test parameters in weekly intervals and that our results can be generalized to all COVID-19
patients, not only to ICU patients. Thirdly, the lack of Doppler US in all patients, that may
diagnose asymptomatic DVT and explain increased D-dimer levels. Finally, our study has an
observational design, so our generated hypothesis must be confirmed and validated in studies
with an appropriate methodology. Despite that, our results could be helpful for the develop-
ment of a new score using our suggested D-dimer dynamics for PE diagnosis in hospitalized
COVID-19 patients.
In conclusion, D-dimer levels are higher at weeks 2, 3 and 4 after onset of symptoms in
COVID-19 patients who develop PE during hospitalization, compared to those who do not
develop PE. This difference is more pronounced when the fold increase between weeks 1 and 2
from symptoms onset is compared. New weekly D-dimer cut-offs should be determined for
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